The LCT 13910 C/T polymorphism as a risk factor for osteoporosis, has no impact on metastatic bone disease in breast cancer

Breast Cancer Research and Treatment

Volumn 112, Issue 2, 2008, Pages 363-365

  Clar, H ^a   Renner, W ^a   Krippl, P ^b   Leithner, A ^a   Gruber, G ^a   Langsenlehner, T ^a   Hofmann, G ^a   Yazdani Biuki, B ^a   Clar, V ^a   Windhager, R ^a   Langsenlehner, U ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; BONE METABOLISM; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LACTOSE INTOLERANCE; LETTER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROMETASTASIS; OSTEOCLAST; OSTEOPOROSIS; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; LACTOSE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOPOROSIS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 54049088611     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9863-6     Document Type: Letter

References (21)

1. JE Brown H Neville-Webbe RE Coleman 2004 The role of bisphosphonates in breast and prostate cancers Endocr Relat Cancer 11 2 207 24 Review
2. Fokas E, Engenhart-Cabillic R, Daniilidis K, Rose F, An HX (2007) Metastasis: the seed and soil theory gains identity. Cancer Metastasis Rev Sep 5 [Epub ahead of print]
3. M McClung 2007 Role of RANKL inhibition in osteoporosis Arthritis Res Ther 9 Suppl 1 S3
4. M Cicek MJ Oursler 2006 Breast cancer bone metastasis and current small therapeutics Cancer Metastasis Rev 25 4 635 44 Review
5. T Yoneda A Sasaki GR Mundy 1994 Osteolytic bone metastasis in breast cancer Breast Cancer Res Treat. 32 1 73 84
6. BM Obermayer-Pietsch CM Bonelli DE Walter RJ Kuhn A Fahrleitner-Pammer A Berghold W Goessler V Stepan H Dobnig G Leb W Renner 2004 Genetic predisposition for adult lactose intolerance and relation to diet, bone density, and bone fractures J Bone Miner Res 19 1 42 47
7. P Krippl U Langsenlehner W Renner 2004 The 825C > T polymorphism of the G-protein beta-3 subunit gene (GNB3) and breast cancer Cancer Lett 206 1 59 62
8. M de Vrese A Stegelmann B Richter S Fenselau C Laue J Schrezenmeir 2001 Probiotics-compensation for lactase insufficiency Am J Clin Nutr 73 2 Suppl 421 429
9. K Terrio GW Auld 2002 Osteoporosis knowledge, calcium intake, and weight-bearing physical activity in three age groups of women J Community Health 27 5 307 320
10. KE Scholz-Ahrens P Ade B Marten P Weber W Timm Y Asil CC Gluer J Schrezenmeir 2007 Prebiotics, probiotics, and synbiotics affect mineral absorption, bone mineral content, and bone structure J Nutr 137 3 Suppl 2 838 846
11. BM Obermayer-Pietsch M Gugatschka S Reitter W Plank A Strele D Walter C Bonelli W Goessler H Dobnig C Högenauer W Renner A Fahrleitner-Pammer 2007 Adult-type hypolactasia and calcium availability: decreased calcium intake or impaired calcium absorption? Osteoporos Int 18 4 445 451
12. S Paget 1989 The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 8 2 98 101
13. D Shoback 2007 Update in osteoporosis and metabolic bone disorders J Clin Endocrinol Metab 92 3 747 53 Review
14. Roodman GD (2004) Mechanisms of bone metastasis, Review. N Engl J Med 15; 350(16):1655-1664
15. Clemons M, Dranitsaris G, Ooi W, Cole DE (2007) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 2007 May 2 [Epub ahead of print]
16. Jaschke A, Bastert G, Solomayer EF et al (2004) Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow-a longtime follow-up. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 529
17. Powles T, McCloskey E, Kurkilahti M (2004) Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 528
18. Saarto T, Vehmanen L, Blomqvist C, Elomaa I (2004) Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. J Clin Oncol 22 (14S, 2004 ASCO Annual Meeting Proceedings, Post-Meeting Edition): Abstract 527
19. JJ Body T Facon RE Coleman 2006 A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer Clin Cancer Res 12 4 1221 1228
20. McClung MR, Lewiecki EM, Cohen SB et al (2006) AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821-831
21. Clar H, Langsenlehner U, Krippl P, Renner W, Leithner A, Gruber G, Hofmann G, Yazdani-Biuki B, Langsenlehner T, Windhager R. A polymorphism in the G protein beta3-subunit gene is associated with bone metastasis risk in breast cancer patients. Breast Cancer Res Treat 2007 Nov 4 [Epub ahead of print]